Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: An administrative claims analysis

Health care resource utilization and costs among adult patients with hemophilia A on factor VIII prophylaxis: An administrative claims analysis

BACKGROUND: Standard of care for bleed prevention in patients with severe congenital hemophilia A is continuous prophylaxis with factor VIII (FVIII), typically administered intravenously 2-3 times per week in the home setting. Nonfactor prophylaxis and gene therapy are emerging novel prophylaxis str...

Full description

Bibliographic Details
Main Authors: Chawla, A. (Author), Cook, K. (Author), Croteau, S.E (Author), Hinds, D. (Author), Kim, B. (Author), Sammon, J. (Author), Sheikh, L. (Author), Solari, P. (Author), Thornburg, C.D (Author)
Format: Article
Language:English
Published: Academy of Managed Care Pharmacy (AMCP) 2021
Subjects:
activated prothrombin complex
adolescent
Adolescent
adult
Adult
Article
blood clotting factor 8
cohort analysis
comparative study
controlled study
disease severity
drug administration
Drug Administration Schedule
emergency ward
emicizumab
Factor VIII
female
Female
health care cost
Health Care Costs
health care quality
health care utilization
health economics
health insurance
Healthcare Common Procedure Coding System
hemophilia A
Hemophilia A
hospital cost
human
Humans
ICD-10-CM
ICD-9-CM
Infusions, Intravenous
insurance
Insurance Claim Review
intravenous drug administration
major clinical study
male
Male
middle aged
Middle Aged
nonviral gene therapy
Patient Acceptance of Health Care
patient attitude
recombinant blood clotting factor 7a
reimbursement
Retrospective Studies
retrospective study
United States
young adult
Young Adult
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items